Skip to content

Replimune Group REPL Other accrued liabilities

Other accrued liabilities at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
Tango Therapeutics logo
Tango TherapeuticsTNGX
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Immunovant, Inc. logo
Immunovant, Inc.IMVT
Roivant Sciences logo
Roivant SciencesROIV
Nektar Therapeutics logo
Nektar TherapeuticsNKTR

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's other accrued liabilities?
Replimune Group (REPL) reported other accrued liabilities of $1.24M in Q4 2025.
How has Replimune Group's other accrued liabilities changed year-over-year?
Replimune Group's other accrued liabilities decreased by 71.2% year-over-year, from $4.31M to $1.24M.
What is the long-term trend for Replimune Group's other accrued liabilities?
Over 4 years (2021 to 2025), Replimune Group's other accrued liabilities has grown at a 85.4% compound annual growth rate (CAGR), from $514K to $6.07M.